



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

REC'D 3.0 APR 2004

WIPO

PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

03007677.2

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**



Anmeldung Nr.:  
Application no.: 03007677.2  
Demande no:

Anmeldetag:  
Date of filing: 03.04.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Vitamins AG

4070 Basel  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Powderous formulations of fat-soluble active ingredients

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A23D/

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT SE SI SK TR LI

Roche Vitamins AG, CH-4070 Basle, Switzerland

Case 21722

Powderous formulations of fat-soluble active ingredients

The present invention is concerned with novel stable powderous formulations comprising a fat-soluble active ingredient, and a process for their preparation. The novel compositions  
5 of this invention can be used as additives for food, beverages, animal feeds, cosmetics or drugs to incorporate said fat-soluble ingredients into such application forms.

More specifically, the present invention is concerned with stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition.

10 As used herein, the term "native lupin protein" denotes a lupin protein as it is found in natural products such as lupin seeds and has not been modified by hydrolysis. However, the term „native lupin protein“ is understood to include lupin proteins which have undergone post-isoelectric precipitation and are generally known as "restructured" proteins, see international patent application WO 99/11143 and references contained  
15 therein.

The term "native lupin protein composition" denotes any composition comprising native lupin protein as obtainable from natural lupin protein sources. Examples of such native

lupin protein compositions are lupin protein concentrates, which have a protein content of 60 % up to 90 % by weight (hereinafter : wt.-%), generally from 50-96 wt.-%, typically  
20 about 65-70 wt.-% of protein; and lupin protein isolates, which term is generally used in the art to define protein preparations containing more than about 90 wt.-% of protein.

Grn/fm; 03.04.2003

- 2 -

The residual constituents (4-50 wt.-%) of such concentrates and isolates are, besides water and oil, primarily plant fibers.

For the purpose of the present invention, lupin concentrates having a protein content of about 60- 90 wt.-%, isolates having a protein content of more than 90 wt.-%, and flours  
5 having a protein content of about 40-60 wt.-%,

are preferred. As a source for the protein compositions all known lupin varieties, such as

Lupine Angustifolius, Lupine Albus oder Lupine Luteus can be used. However, protein compositions derived from Lupine Angustifolius and Lupine Albus are preferred.

The term "fat-soluble active ingredient" as used herein denotes any physiologically active  
10 ingredient that is soluble in lipids and insoluble or sparingly soluble in water. Examples of such fat-soluble active ingredients are fat-soluble vitamins, viz., vitamin A, D, E and K and derivatives thereof such as vitamin A esters, e.g. vitamin A acetate and palmitate, and vitamin E esters, e.g. tocopherol acetate; carotenoids and carotinoid derivatives, e.g., are  $\alpha$ - or  $\beta$ -carotene, 8'-apo- $\beta$ -carotenal, 8'-apo- $\beta$ -carotenoic acid esters such as the ethyl ester,  
15 canthaxanthin, astaxanthin, astaxanthin esters, lycopene, lutein, zeaxanthin or crocetin and their derivatives; polyunsaturated fatty acids, e.g. eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid and  $\gamma$ -linolenic acid and/or ethylester.

In a preferred aspect of the invention, the novel formulations additionally contain a reducing sugar, e.g. glucose, fructose, saccharose or xylose. Such formulations can be  
20 submitted to heat-treatment to cause cross-linking of the sugar with the protein in a Maillard type reaction. Crosslinking can be also achieved by treatment with enzymes like transglutaminase. The cross-linked formulations have been found to exhibit increased stability.

In accordance with the invention, the novel formulations can be obtained by a process  
25 which comprises preparing an aqueous emulsion of the fat-soluble active ingredient and the native lupin protein composition, if desired, adding a reducing sugar, converting the emulsion into a dry powder and, if a reducing sugar was added, submitting the dry powder to cross-linking the sugar with the protein by heat treatment or by treatment with a cross-linking enzyme.

30

- 3 -

Suitably, in a first step of the process of the invention, the protein composition is dispersed in water. Thereafter, the fat-soluble active ingredient is emulsified, suitably in liquid state, i.e. with adequate warming and/or as a solution in an appropriate solvent, into the aqueous dispersion of the protein. Alternatively a suspension of the solid active may be produced by appropriate procedures like milling. The emulsion is then, optionally after removal of excess solvent, spray-dried. The spray-drying can be effected by using conventional technology of spray-drying, spray drying in combination with fluidized-bed granulation (the latter technique commonly known as fluidized spray drying or FSD), or by a powder-catch technique where sprayed emulsion droplets are caught in a bed of an absorbant such as starch or calcium silicate and subsequently dried.

In still another aspect of the invention, the novel formulations may additionally contain other proteins or hydrolyzed proteins that act as protective colloids, e.g. soy proteins or, hydrolyzed soy proteins. Such additional proteins may be present in the formulations of the invention in an amount of from 10-50 wt.-% based on the total amount of protein in the formulation.

Finally, in a still further aspect, the present invention is concerned with food, beverages, animal feeds, cosmetics and drugs which comprise the novel formulations of the present invention.

The novel formulations of this invention may further contain adjuvants and/or excipients such as one or more of a mono- di-, oligo- or polysaccharide, a triglyceride, a water-soluble antioxidant, a fat-soluble antioxidant, silicic acid, Ca-silicate, Ca-carbonate and water.

Examples of mono- and disaccharides which may be present in the formulations of the present invention are saccharose, invert sugar, glucose, fructose, lactose and maltose. Examples of oligo- or polysaccharides which may be present in the compositions of the present invention are starch, modified starch and starch hydrolysates, such as dextrans and maltodextrans, especially such in the range of 5-65 dextrose equivalents (hereinafter: DE) and glucose syrup, especially such in the range of 20-95 DE. The term "dextrose equivalent" (DE) denotes the degree of hydrolysis and is measure for the amount of reducing sugar calculated as D-glucose based on dry weight. Native starch has DE close to 0 while glucose has a DE = 100.

The triglyceride is suitably a vegetable oil or fat, such as corn oil, sunflower oil, soybean oil, safflower oil, rape seed oil, arachis oil, palm oil, palm kernel oil, cotton seed oil or cocos oil.

The water-soluble antioxidant may be ascorbic acid and salts thereof, e.g., sodium ascorbate, and the like. The fat-soluble antioxidant may be a tocopherol, e.g., dl- $\alpha$ -tocopherol (i.e., synthetic tocopherol), d- $\alpha$ -tocopherol (i.e., natural tocopherol),  $\beta$ - and  $\gamma$ -tocopherol and mixtures thereof; ascorbic acid esters of fatty acids such as ascorbyl palmitate or stearate; butyl hydroxy toluene (BHT); butyl hydroxy anisol (BHA); propyl gallate; or t-butyl hydroxy quinoline; or 6-ethoxy-1,2-dihydroxy-2,2,4-trimethylquinoline (EMQ).

The following Examples illustrate the invention further.

#### Example 1

Preparation of a powderous vitamin A formulation:

62.4 g of lupin protein isolate from Lup. Angustifolius (protein content 96.2%) and 10.9 g of glycerol were added to 230 ml of water. The mixture was warmed to 60 °C until dissolution occurred. To this solution, 12.3 g of fructose were added and the pH of the solution was adjusted to  $6.5 \pm 0.2$ . Thereafter, 49.3 g of vitamin A acetate ( $2.1 \times 10^6$  IE vitamin A /g stabilized with Ethoxyquin) were emulsified into the matrix solution whereupon the mixture was stirred for 60 minutes at 60 °C. The inner phase of the emulsion then exhibited a mean particle size of about 580 nm. The emulsion was then diluted with ca. 25 ml of water and about 300 g of the emulsion was sprayed in a spraying pan in a bed of Ca-silicate at about 5° C by means of a rotating spraying nozzle. The so-obtained beadlets were separated from excess Ca-silicate by sieving and dried. There were obtained ca. 100 g of dry powder having a vitamin A content of ca. 850'000 IEA/g.

#### Example 2

Thermal cross-linking :

The vitamin A dry powder obtained in Example 1 is stirred at a temperature of 135 °C for 35 minutes. The so-obtained product was insoluble in hot water and had a vitamin A content of ca. 570'000 IEA/g.



### Example 3

Preparation of an ethyl apo-carotenoate dry powder :

- a) 16 g of lupin protein isolate from *Lup. Angustifolius* (protein content 96.2%) were dissolved in 130 ml of water at 50° C. To this solution, 1.6 g of ascorbylpalmitate were added and the pH of the solution was adjusted to  $7.5 \pm 0.2$  by the addition of 20 wt.-% sodium hydroxide solution.
- b) 9 g of ethyl  $\beta$ -apo-8'-carotenoate, 5.5 g of corn oil and 0.6 g of Ethoxyquin were dissolved in 50 ml of chloroform.
- c) The ethyl  $\beta$ -apo-8'-carotenoate solution obtained in paragraph b) was emulsified during 30 minutes at 45° C into the solution obtained in paragraph a). The inner phase of the emulsion then exhibited a mean particle size of about 280 nm. The chloroform was evaporated at 50° C under reduced pressure and the emulsion was spray-dried in analogy to the procedure of Example 1 in a bed of starch. There were obtained 42 g of dry powder having an ethyl  $\beta$ -apo-8'-carotenoate content of 11,4 wt.-%.

- 6 -

What is claimed is:

1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition.
2. Formulations according to claim 1, wherein the lupin protein composition is a lupin  
5 protein isolate having a protein content of more than 90 wt.-%.
3. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.
4. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.
- 10 5. Formulations according to claim 1, comprising mixtures of native lupin protein compositions as defined in claims 2-4.
6. Formulations according to claim 1, wherein the fat-soluble active ingredient is vitamin A, D, E or K, or a carotenoid, or a polyunsaturated fatty acid, or esters thereof, or mixtures thereof.
- 15 7. Formulations according to claim 1, wherein the fat-soluble active ingredient is a plant or animal oil or fat, particularly sunflower oil, palm oil or corn oil.
8. Formulations according to claim 1, comprising additionally a reducing sugar, particularly glucose, fructose, saccharose or xylose.
9. Formulations according to any one of claims 1- 8, wherein the protein is cross-linked.
- 20 10. Food, beverages, animal feeds, cosmetics or drugs comprising a formulation according to any one of claims 1- 9.
11. Process for the preparation of formulations according to any one of claims 1- 9, which comprises preparing an aqueous emulsion of the fat-soluble active ingredient and the native lupin protein composition, if desired, adding a reducing sugar, converting the  
25 emulsion into a dry powder, and, if required, submitting the dry powder to cross-linking the protein by heat treatment or by treatment with a cross-linking enzyme.



- 7 -

12. A process according to claim 11 wherein a reducing sugar is added and the composition is submitted to crosslinking by heating.

13. A process according to claim 11 wherein the composition is submitted to crosslinking by treatment with a cross-linking enzyme, particularly transglutaminase.

5

\*\*\*